Patent EA-000697-B1 (EA)
Title: Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition
Inventor: ARCAMONE FEDERICO
IPC: A61P9/12
Filed: 1996-03-11
Abstract: 1. Bicyclic compounds of general formula   wherein X1, X2, X3, X4, X5 and X6, same or different from one another, present a -NR'CO- or a -CONR'- group, where R' is H or C1-C3 alkyl; Y represents a group selected from -NRCO-. -CONR- or -SS- wherein R is H or C1-C3 alkyl; at least one of R1, R2, R3 and R4 groups, same or different from one another, is hydrophilic and the remaining groups are hydrophobic; m and n, same or different from one another, are each an integer number from 1 to 4 2. Compounds as claimed in claim 1, wherein the hydrophobic groups can be separately selected from the following: a) groups corresponding to CnH2n+1 wherein n= 0, 1-4; b) linear or branched-alkyl groups corresponding to CnH2n-U-W wherein n= 1-4; U= O, COO, CONH, S and W= alkyl-, aryl- or alkylaryl-group containing from 1 to 15 C atoms; c) (CH2)n-C6H3-A-B wherein n= O. 1-3; A and B, placed in any of the ortho. meta or para positions. same or different from one another represent H. halogen, OR. NHR, NR2. CH3. SR wherein R is an alkyl-.aryl- or alkylaryl-group with less than 10 C atoms; d) (CH2)n-C6H10 R', wherein n= 0, 1-3 and R'= H. C1-C3 alkyl; e) (CH2)n-heterocycle, wherein n= 0, 1-3 and by the term heterocyclic imidazolyl-2-yl, indolyl-3-yl, furanyl-3-yl, piridyl-3-yl, imidazolyl-3-yl are meant; f) a -(CH2)s- group wherein s = 3, 4, eventually OH-substituted or condensed with an aromatic group, which cyclizes with one of the two adjacent X1-6 groups in order to produce the side chain of proline, hydroxyproline, octahydroindol-2-carboxylic acid, tetrahydroisoquinolinic acid; g) the side chain of a natural hydrophobic amino acid; h) the side chain of a natural hydrophilic amino acid, suitably substituted in order to render it hydrophobic; i) the side chain of non-natural hydrophobic amino acids selected from the group consisting of: norleucine, norvaline, alloisoleucine, ciclohexylglycine (Chg). α-amino-n-butyric-acid (Aba), ciclohexylalanine (Cha). aminophenylbutyric acid (Pba), mono- and disubstituted phenylalonines in ortho, meta and para positions of the benzene ring with one or more of the following groups: C1-C 10 alkyl, C1-C 10 alkoxy, halogen, β-2-thienylalanine, β-3-thienylalanine, β-2- furanylalanine, β-3-furanylalanine, β-2-piridylalanine, β-3- piridylalanine, β-4-piridylalanine, β-(l-naphtyl)alanine, β-(2- naphtyl ) alanine, O-alkylated serine-threonine- tyrosine-derivatives, S-alkyl cysteine, S-alkyl homocysteine, N-alkyl lysine, N-alkyl ornithine. N-alkyl 2,3 diaminopropionic acid. 3. Compounds as claimed in claim 2 wherein the side chain of a hydrophobic amino acid according to paragraph g) is the side chain of an amino acid selected from the group consisting of: glycine, alanine, valine, leucine. isoleucine, methionine, phenylalanine. tyrosine, tryptophan, proline, histidine. aspargine, glutamine. 4. Compounds as claimed in claim 2, wherein the side chain of an hydrophilic amino acid suitably substituted according to paragraph (h) is the side chain of an amino acid selected from the group consisting of: serine, threonine, cysteine, aspartic acid, glutamic acid, tcarboxyglutamic acid, arginine. ornythine, lysine. 5. Compounds according to claim 2 wherein the hydrophilic groups are chosen in the group L-Q wherein L is a chemical bond or a linear or branched C1-C6 alkyl-group and Q is chosen in the group consisting of: i) hydroxyl. amine, guanidine, carboxyl, sulfate. phosphonate, phosphate; ii) linear, branched or cyclic C1-C6 alkyl chain containing one or more hydroxyl. amine, guanidine, carboxyl, sulfate, phosphate; iii) an aromatic group mono-, di- or tri-substituted ortho-, meta-, para-position with hydroxyl, amino. guanidine, carboxyl. sulfate, phosphate; iv) a group M, OM, CONHM, NHCOM wherein M is an hydrophilic group; v) an hydrophilic group according to points i)-iv) protected with groups which are biologically hydrolized reforming an hydrophilic group. 6. Compounds according to claim 5 wherein the group M is chosen in the group consisting of: i) eventually substituted mono-. di-, tri-glycosidic residues; ii) linear, branched or cyclic C1-C6 alkyl-chains, containing one or more groups hydroxyl, amine, guanidine, carboxyl, sulfate, phosphonate. phosphate. 7. Compounds of formula (I) as claimed in claim 6, wherein the glycosidic residues are selected from the group consisting of: hexoses or pentoses of D or L series in α or β configuration, selected from the group wherein: all C atoms bear a free or protected hydroxylic group; one or more hydroxyls are substituted by: hydrogen; an amino or acylamino group; C6 of hexoses and C5 of pentoses are part of a carboxylic group; and wherein the eventually present 2 or 3 glycosidic units are linked by a glycosidic bond of α or β configuration. 8. Compounds of general formula (I) according to claim 7 selected from the group consisting of: D or L ribose, D or L arabinose, D or L xylose, D or L lyxose. D or L allose, D or L altrose, D or L glucose, D or L mannose, D or L gulose, D or L idose, D or L galactose, D or L talose, D or L allulose, D or L fructose, D or L sorbose, D or L tagatose, 5-deoxy-D or L-arabinose, 2-deoxy-D or L-glucose, 2-deoxy-D or L-galactose, 2-deoxy-D or L-arabinose, 2-deoxy-D or L-ribose, D or L fucose, D or L ramnose, D-glucosamine, D-mannosamine, Dgalactosamine, daunosamine, acosamine and N-acylate derivates thereof with lower fat acids, i.e. containing a N-formylic, acetylic, propionilic, butyric residue, glucuronic acid, galacturonic acid, cellobiose, lactose, maltose, D-lactosamine, cellotriose. Maltotriose, tris(hydroxymethyl)methyl, D or L arabitol, D or L erythrol, D or L perseitol, D or L ribitol, D or L sorbitol, D or L xylitol; or those from the residue of tartaric acid, glucaric acid, gluconic acid, bycine, quinic acid, mucic acid, glucosaminic acid. 9. Compounds of general formula (I) according to claim 1, wherein if one or both R1 and R4 groups are hydrophilic both R2 and R3 groups are hydrophobic or viceversa. 10. Compounds as claimed in claim 1, as hereinafter indicated: i) cyclo([Asn(β-D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2β -5β)) (SEQ ID No. 1) ii) cyclo([Ser(β-D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No.2) iii) cyclo ([Asn (β-D-2-deoxy-2-amino-Glc)-Asp-Trp-Phe-Dap-Leu] cyclo (2 β-5β)) (SEQ ID No. 3) iv) cyclo ([Asn(β-D-2-deoxy-2-acetamido-Glc)-Asp-Trp-Phe-Dap- Leu]cyclo(2β-5β)) (SEQ ID No. 4) v) cyclo([Nle-Asp-Trp-Phe-Dap-Asn(β-D-2-deoxy-2-acetamido-Glc)] cyclo(2β-5β)) (SEQ ID No. 5) vi) cyclo ([Asn(β-D-ribofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo (2β-5β)) (SEQ ID No. 6) vii) cyclo ([Ser(β-D-ribofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo (2β-5 )) (SEQ ID No. 7) viii) cyclo([Asn(β-L-arabinofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo (2β-5β)) (SEQ ID No. 8) ix) cyclo([Ser(β-L-arabinofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo (2β-5β)) (SEQ ID No. 9) x) cyclo([Asn(β-D-mannopyranosyl)-Asp-Trp-Phe-Dap-Leu] cyclo(2β-5β)) (SEQ ID No. 10) xi) cyclo([Ser(β-D-mannopyranosyl)-Asp-Trp-Phe-Dap-Leu] cyclo(2β-5β)) (SEQ ID No. 11) xii) cyclo([Asn(β-D-galactopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo (2β-5β)) (SEQ ID No. 12) xiii) cyclo([Ser(β-D-galactopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo (2β-5β)) (SEQ ID No. 13)\ xiv) cyclo ([Asn(β-D-glucuronopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 14) xv) cyclo ([Ser(β-D-glucuronopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 15) xvi) cyclo ([Asn(l-deoxy-sorbitol-l-yl)-Asp-Trp-Phe-Dap-Leu]cyclo (2β-5β)) (SEQ ID No. 16) xvii) cyclo ([Asn [(4-O-(α-D-Glc)-β-D-Glc)]-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 17) xviii) cyclo ([Asn[(4-O-(α-D-galactopyranosyl)-β-D-Glc)]-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 18) xix) cyclo ([Asn [O-α-D-Glc-(1-4)-O-α-D-Glc-(1-4)-α-D-Glc]-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 19) xx) cyclo ([Asn(D-2-deoxy-glucopyranos-2-yl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 20) xxi) cyclo ([Dap[D(-)-quinyl]-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 21) xxii) cyclo ([Dap[D-gluconyl]-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 22) xxiii)cyclo ([Dap[D-glucuryl]-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 23) xxiv) cyclo([Dap(2-sulfo-benzoyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 24) xxv) cyclo ([Asn(4-sulfo-phenyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 25) xxvi) cyclo ([Asn(β-L-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 26) xxvii) cyclo ([Asn(β-D-2-deoxy-glucopyranos-2-yl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 27) xxviii) cyclo ([Asn(β-D-2-deoxy-mannopyranos-2-yl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 28) xxix) cyclo ([Asn(D-2-deoxy-galactopyranos-2-yl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 29) xxx) cyclo ([Asn(β-D-xylopyranosyl)-Asp-Trp-phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 30) xxxi) cyclo ([Asn(3-sulfo-propionyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 31) xxxii) cyclo ([Dap(Lysyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 32) xxxiii) cyclo ([Dap(Arginyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 33) xxxiv) cyclo ([Dap(4-O-β-D-galactopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 34) xxxv) cyclo ([Asn(2-deoxy-2-trifluoroacetamido-β-D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)) (SEQ ID No. 35). 11. Pharmaceutical compositions containing as active principle compounds of general Formula (I) as claimed in claim 1 combined to suitable carriers in an effective amount. 12. Methods for treatment of arthrytis, asthma, inflammations, tumoral growth, gastr